Oral Azacitidine Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma
Status:
Active, not recruiting
Trial end date:
2023-03-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and tolerability of adding oral
azacitidine to the chemotherapy combination R-ICE. This study will also look at whether or
not disease outcomes improve with the combination.